Has Jacob Nysather, DO received payments from drug or device companies?

Yes. Drug and device makers reported $14,586 in general payments to Jacob Nysather, DO across 59 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Jacob Nysather, DO did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Jacob Nysather, DO come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Jacob Nysather, DO

Nephrology · Montgomery, OHNPI 1407376312

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $8,990 of the $14,586 with a category attached, or 61.6%. AstraZeneca accounts for 67.9% of it on its own, with 22 other manufacturers making up the rest. 2025 is the largest year on record at $11,709, more than ten times the $64 reported in 2019. Among nephrology clinicians in OH with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$14,586in general payments, 2019–2025

Across 59 payments — averaging $247.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AstraZeneca$10K
Baxter Healthcare$1K
Vifor Pharma, Inc.$529
Amgen$510
Apellis Pharmaceuticals, Inc.$425
Nxstage Medical, Inc.$382
plus $2K from 17 others

What the payments were for

Consulting fees$8,99062%
Travel & lodging$6554%
Food & beverage$4,94134%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AstraZeneca	8	$9,899
Baxter Healthcare	8	$1,095
Vifor Pharma, Inc.	5	$529
Amgen	5	$510
Apellis Pharmaceuticals, Inc.	3	$425
Nxstage Medical, Inc.	6	$382
Mallinckrodt Hospital Products Inc.	3	$338
Travere Therapeutics, Inc.	3	$254
Akebia Therapeutics Inc	2	$204
Alnylam Pharmaceuticals Inc.	1	$147
Sanofi	1	$136
Otsuka America Pharmaceutical, Inc.	2	$117
Outset Medical Inc	2	$100
Novo Nordisk	1	$99
Otsuka Pharmaceutical Development & Commercialization, Inc.	1	$97
Calliditas Therapeutics US Inc.	1	$89
Novartis	1	$45
QOL Medical, LLC	1	$30
Ardelyx, Inc.	1	$25
Takeda Pharmaceuticals U.S.A., Inc.	1	$21
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)	1	$19
E.r. Squibb & Sons, L.L.C.	1	$13
Amarin Pharma, Inc.	1	$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,586 in reported general payments places this provider in the 90th percentile of 450 nephrology providers in Ohio.

See all nephrology providers in Ohio →

Medicare billing

Part B allowed, 2024

$57,465

Medicare patients

179

Services billed

590

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
XphozahTenapanor Hcl	15	$60,099
JardianceEmpagliflozin	21	$16,975
Sevelamer Carbonate	22	$3,862
Calcium Acetate	14	$938
Torsemide	14	$651
Nifedipine ErNifedipine	49	$461
Potassium Chloride	23	$317
Metoprolol Succinate	11	$175
Lisinopril	27	$153
Spironolactone	67	$133
Losartan Potassium	29	$124
Carvedilol	37	$100
Amlodipine Besylate	12	$95
Furosemide	38	$89

Paid to pharmacies, not to this prescriber.

Other nephrology in Montgomery

Brad RovinColumbus$379K
Nissreen ElfadawyChardon$327K
Andrew LazarBeachwood$315K
Amit GovilCincinnati$298K
Georges NakhoulCleveland$255K
Sankar NavaneethanCleveland$253K
Ibrahim AhmadKettering$232K
Prabir Roy ChaudhuryCincinnati$205K
Rupesh RainaAkron$163K
Sevag DemirjianCleveland$158K

See the full list for Ohio →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →